Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | GLO1 | Q04760 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
| ▸ | LY96 | Q9Y6Y9 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6422006 | 0.77 | ALDH1A1 (0.37) | KDM4ENPC1RAB9AHDAC8LMNA | |
| SCHEMBL6422010 | 0.77 | ALDH1A1 (0.37) | KDM4ENPC1RAB9AHDAC8LMNA | |
| SCHEMBL7795166 | 0.70 | EPHX2 (0.38) | EPHX2ALDH1A1 | |
| SCHEMBL7934147 | 0.69 | GSK3B (0.50) | KDM4ENPC1RAB9AHDAC8GLO1 | |
| SCHEMBL7617840 | 0.69 | GSK3B (0.50) | KDM4ENPC1RAB9AHDAC8GLO1 | |
| SCHEMBL26565527 | 0.69 | HPGD (0.40) | KDM4EHDAC8LMNAMAPTLY96 | |
| SCHEMBL9023562 | 0.67 | ALDH1A1 (0.55) | KDM4EGLO1LMNAMAPTALDH1A1 | |
| Benzene SCHEMBL27424700 | 0.67 | ALDH1A1 (0.55) | KDM4EGLO1LMNAMAPTALDH1A1 | |
| SCHEMBL9023565 | 0.67 | ALDH1A1 (0.55) | KDM4EGLO1LMNAMAPTALDH1A1 | |
| SCHEMBL25653166 | 0.66 | ALDH1A1 (0.41) | KDM4ENPC1RAB9ALMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010014737-A1 | Vitronectin receptor antagonist | HEERDING DIRK (US) | 2001-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010014737-A1 | Vitronectin receptor antagonist | CALCR, ADGRF1, CALCRL | KDM4E 4754/4885NPC1 1170/4885RAB9A 1830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.